Increase in cosmetics production and sales results
First written in FY2017-Q3. 1 of 29 entries say "Advanced", first in FY2017. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Recovery in the core serum and weak performance of regular productsAnnual report
「Shipments of the strengthened product Red Power Serum increased to 18,058 sets, compared with 17,903 sets in the previous fiscal year. Meanwhile, White Power Serum (a quasi-drug) remained sluggish at 10,529 sets, compared with 10,710 sets in the previous fiscal year. Regular products also remained sluggish.」
Red Power Serum exceeded the previous fiscal year, while White Power Serum and regular products were weak, and the performance gap by product category persisted. - FY2026-H1Growth in core serum sales alongside weak regular productsAnnual report
「Sales initiatives for Red Power Serum, one of our core products, were successful, and shipments totaled 17,083 sets, above the 16,513 sets in the previous interim accounting period. Regular products continued to struggle, but despite the absence of new product launches during the interim accounting period, total sales increased slightly.」
Shipments of Red Power Serum increased, while regular products continued to struggle, and the performance gap between product groups persisted. - FY2025Recovery in core serum sales and differences in performance by product categoryAnnual report
「Shipments of Red Power Serum recovered to 17,903 sets, compared with 16,473 sets in the previous fiscal year. Meanwhile, shipments of White Power Serum, a quasi-drug, remained sluggish at 10,710 sets, compared with 13,754 sets in the previous fiscal year, partly because the intensive promotion month coincided with the month of a major new product launch.」
Among the core serums, shipments of Red Power Serum increased, while shipments of White Power Serum declined. - FY2025-H1Recovery in core serum sales and strong regular products alongside insufficient orders for new productsAnnual report
「Shipments of Red Power Serum totaled 16,513 sets, below the target of 20,000 sets but above the 14,766 sets shipped in the previous interim accounting period. Regular products other than new products also performed well. Meanwhile, Euglena Vital EX, a new beauty support product launched in June 2024, generated orders in line with initial expectations, but the order value was below that for new products in the previous interim accounting period.」
Red Power Serum and regular products improved and performed well, while the order value for new products was below that of the previous interim period, and the gap between product groups persisted. - FY2024Overall revenue decline and differences by product categoryAnnual report
「Total skincare sales were ¥1,979.210 million, down 3.3% from the previous fiscal year. … Total haircare sales were ¥119.321 million, down 56.4%. … Sales in the cosmetics segment were ¥2,348.656 million, down 8.9%.」
Skincare, including the new facial cleansing series, declined slightly, haircare declined sharply, and total cosmetics segment sales declined 8.9%. - FY2024-Q3Strong performance by new and regular products alongside sluggish core serum salesAnnual report
「During the cumulative third quarter, the new facial cleansing series Ivy Attracty, launched in June 2023, generated orders exceeding initial expectations, with all products being quasi-drugs. Lip Repair Cream, a lip treatment also launched in June 2023, likewise generated strong orders, and although additional production was undertaken, some units were not ready for shipment in September. … Shipments of Red Power Serum during the cumulative third quarter totaled 14,964 sets, below the 17,470 sets shipped in the cumulative period of the same quarter of the previous year, reflecting continued difficulties.」
New products such as the facial cleansing series and Lip Repair Cream performed well, while shipments of Red Power Serum were below the level of the same period of the previous year, and the performance gap between product categories persisted. - FY2024-Q2Strong performance by new and regular products alongside sluggish core serum salesAnnual report
「The new facial cleansing series Ivy Attracty was well received, and its strong performance spread to other regular products.」
New and regular products performed well, while shipments of Red Power Serum totaled 14,766 sets, below the 17,297 sets shipped in the same period of the previous year, and the performance gap between product groups persisted. - FY2024-Q1Strong performance by new products and growth in regular productsAnnual report
「Overall, orders for regular products remained above the level in the cumulative period of the same quarter of the previous year. Strong performance by the new facial cleansing series Ivy Attracty was beginning to spread to other regular products.」
The strong performance of Ivy Attracty spread to other regular products, and orders for regular products exceeded the level of the same period of the previous year. - FY2023Differences in sales by product group and overall revenue declineAnnual report
「Total skincare sales were ¥2,047.444 million, down 19.9% from the previous fiscal year. Total makeup sales were ¥231.624 million, up 0.9%, and total haircare sales were ¥273.359 million, up 64.0%.」
Core skincare sales declined 19.9%, while makeup and haircare sales increased 0.9% and 64.0%, respectively, and the performance gap between product categories persisted. - FY2023-Q3Lower revenue due to weak distributor sales alongside improving customer metricsAnnual report
「The number of new Ivy Mates customers increased approximately 19% from the cumulative period of the same quarter of the previous year, while the number of new sales offices, which serve as sales locations, remained at roughly the same level as in the cumulative period of the same quarter of the previous year. The number of training sessions and group events, as well as participation in them, which are central to our strength in developing people, also gradually recovered, although regional disparities remained.」
Although the increase in Ivy Mates customers and training and group events were improving and recovering, weak sales by distributors affected results, and total sales declined 25.4% year on year. - FY2023-Q2Strong shipments of new products alongside lower revenue from core and regular productsAnnual report
「During the second quarter, we worked to expand sales of regular products, focusing on orders for our core product, Red Power Serum. Second shipments of Medicated Scalp Care Stem Signal, a quasi-drug hair-growth product launched in June, also remained strong. However, the seventh wave of COVID-19 that occurred this summer forced the cancellation or postponement of some group training sessions, and face-to-face sales activities were also severely restricted. Red Power Serum consequently fell short of its initial target, while regular products remained at approximately half the level recorded in the same cumulative quarter of the previous year, when a major skincare series had been launched.」
Second shipments of the hair-growth product were strong, while Red Power Serum fell short of its initial target and regular products were approximately half the level of the same period of the previous year. - FY2023-Q1Strong orders for new products alongside lower regular product revenueAnnual report
「In June, we launched Medicated Scalp Care Stem Signal, a hair-growth product and quasi-drug, which was well received and generated approximately 65,000 orders, exceeding expectations. As a result, about half of the orders were scheduled for shipment during the second quarter. In our year-round efforts to develop loyal users, Ivy Mates increased 37.7% from the cumulative period of the same quarter of the previous year, while the number of participants in philosophy and sales training also increased year on year. Sales activities and development opportunities are gradually returning to pre-pandemic levels, but regular products slowed partly because the effects of stronger orders at the end of the previous fiscal year remained. As a result, regular products declined 20.5% from the cumulative period of the same quarter of the previous year, and sales remained lower.」
Orders for the hair-growth product and sales organization metrics were strong, while regular products slowed and total sales declined 20.5% year on year. The figures show a gap between product and sales metrics. - FY2022Sharp growth in skincare and overall revenue growthAnnual report
「Total skincare sales were ¥2,554.946 million, up 43.2% year on year.」
Skincare, including Ivy Cosmos II, increased 43.2% year on year, and total sales also increased 3.1%. Meanwhile, beauty support products and other products generated lower revenue. - FY2022-Q2Revenue growth from the launch of major new products alongside a shortfall against planAnnual report
「For the six months ended, net sales were ¥1,946 million, up 35.1% from the same cumulative quarter of the previous year. Operating profit was ¥272 million, compared with an operating loss of ¥157 million in the same quarter of the previous year. Ordinary profit was ¥271 million, compared with an ordinary loss of ¥171 million, and net profit for the quarter was ¥197 million, compared with a net loss of ¥160 million.」
Sales activities, including the launch of a major skincare series, drove a 35.1% year-on-year increase in net sales, and operating profit, ordinary profit and net income all turned positive. - FY2022-Q1Steady performance by regular products alongside lower revenue due to sales rebatesAnnual report
「Although no new products were launched during the first quarter, regular products performed steadily. However, net sales declined 1.9% because sales rebates increased from the cumulative period of the same quarter of the previous year.」
Regular products performed steadily despite the absence of new product launches, but net sales declined 1.9% year on year due to an increase in sales rebates. - FY2021Widening performance gaps between product groups and full-year revenue declineAnnual report
「Total skincare sales were ¥1,973.681 million, down 27.5%. Makeup sales were ¥432.291 million, up 32.6%, and haircare sales were ¥248.401 million, up 73.3%. Total sales of beauty support products were ¥1,033.451 million, up 84.0%.」
Core skincare products generated lower revenue, while makeup, haircare and beauty support products generated higher revenue, making the performance gap between product groups clear. - FY2021-Q3Recovery in third-quarter sales alongside a cumulative revenue declineAnnual report
「As a result, sales for the third quarter increased 41.9% from the same quarter of the previous year. However, cumulative sales for the third quarter declined 13.2% year on year, as the increase was not sufficient to offset the decline through the second quarter.」
Third-quarter sales recovered, increasing 41.9% year on year, while cumulative third-quarter sales declined 13.2%. - FY2021-Q2Declines in core and regular product revenue alongside strong performance by new productsAnnual report
「Because orders brought forward ahead of the consumption tax rate increase grew in September of the previous year, regular products declined 41.7% from the cumulative period of the same quarter of the previous year, while orders for Red Power Serum were limited to 65.7% of the level in the cumulative period of the same quarter of the previous year.」
Orders for regular products and core serums declined sharply, while new products, health foods and beauty devices performed well. - FY2021-Q1Decline in existing product revenue and shipments of new products during the pandemicAnnual report
「Sales of regular products declined 51% from the cumulative period of the same quarter of the previous year. With sales activities restricted, we used online tools alongside meetings and gatherings with the sales organization, actively conducting activities on a unit-by-unit basis to promote the adoption of sales initiatives and communicate the appeal of our products.」
Sales of regular products declined 51% year on year due to restrictions on sales activities, while activities with the sales organization were conducted using online tools as well. - FY2020-Q3Growth in core serums and regular products alongside the launch of new productsAnnual report
「During the nine-month period, orders for Red Power Serum increased 48.2% year on year. Regular products remained on an upward trend, increasing 8.1% year on year, as the company continued to rigorously implement its basic activities.」
Sales of core serums and regular products increased year on year, reflecting a recovery in sales from the previous fiscal year. - FY2020-Q2Recovery in core serums and regular products alongside the launch of health foodsAnnual report
「During the six months ended, orders for Red Power Serum increased 52.0% from the same quarter of the previous year. Regular products increased 11.4% year on year as we continued to promote thorough execution of our core business activities. In September, we launched GABA Balance, our first food with function claims, containing GABA, an amino acid, as its functional ingredient. We worked to improve customer satisfaction and expand sales in the health food market.」
Sales of core serums and regular products recovered, while the launch of the first food with function claims expanded the product and market scope. - FY2020-Q1Growth in existing regular products alongside a sharp decline in new productsAnnual report
「Existing regular products, excluding new products, increased 15.5% from the same quarter of the previous year. Meanwhile, sales of new products declined 74.1% year on year, partly because the sales budget for new products was lower than in the same quarter of the previous year.」
Existing regular products increased, while new products declined sharply, and the performance gap between product groups persisted. - FY2019Growth in regular products alongside a sharp decline in serum salesAnnual report
「The significant decline in net sales was mainly due to inventory adjustments by distributors of the enhanced products Red Power Serum, down 81.7% from the previous fiscal year, and White Power Serum, down 86.2%. Regular products performed well, increasing 27.1% from the previous fiscal year.」
Regular products increased 27.1%, while Red Power Serum and White Power Serum declined sharply, widening the performance gap between product groups. - FY2019-Q3Strong performance of regular products and significant decline in the enhanced core productAnnual report
「The main factor behind the significant decline in net sales was inventory adjustments by the sales company for Red Power Serum, the enhanced product, whose sales declined 84.3% from the cumulative third quarter of the previous year. As regular products performed strongly, increasing 30.6% year on year during the current cumulative third quarter, we believe sales to customers by the sales organization remained strong.」
Regular products increased 30.6% year on year, while Red Power Serum declined 84.3%, widening the performance gap between product groups. - FY2019-Q2Increase in regular products alongside decline in orders for the core productAnnual report
「Regular products increased by 14% year on year, but orders for Red Power Serum, now in its third period since launch, differed substantially from the originally planned volume due to the significant impact of inventory adjustments by the sales company.」
The disclosure describes an increase in sales of regular products alongside failure to meet the order plan for Red Power Serum. - FY2018Increase in production alongside decrease in salesAnnual report
「Production results for the consolidated fiscal year by product were skincare at ¥8,962.401 million, 111.1% of the previous period, and Ivy Cosmetics total at ¥9,580.475 million, 111.1%.」
While total production results increased to 111.1% of the previous period, sales results for Ivy Cosmetics totalled ¥5,624.341 million, or 84.4% of the previous period, indicating a decline in sales. - FY2018-Q3Decline in cosmetics sales results for the cumulative third quarterAnnual report
「During the cumulative third quarter of the consolidated fiscal year, cosmetics sales results declined significantly. This was because sales of the new Red Power Serum, launched in the cumulative third quarter of the previous consolidated fiscal year, were sluggish during the current cumulative third quarter.」
The company states that sluggish sales of Red Power Serum led to a significant decline in cosmetics sales results. - FY2017AdvancedAnnual report
「Production results for the consolidated fiscal year by product were skincare at ¥8,063.436 million, 157.9% of the previous period; Ivy Cosmetics total at ¥8,623.184 million, 152.3%; and total at ¥8,623.184 million, 152.2%.」
Against the backdrop of expanded sales of Red Power Serum and other products, total production results reached 152.2% of the previous period, while total sales results reached 129.1%. - FY2017-Q3First statedAnnual report
「During the cumulative third quarter of the consolidated fiscal year, cosmetics production and sales results increased significantly. This was because attendance at various training programs and the opening of additional sales offices progressed smoothly, and sales of the new Red Power Serum performed well.」
The company cited training attendance, the opening of additional sales offices and strong sales of Red Power Serum as factors behind the significant increase in cosmetics production and sales results.